Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYBL1
REST API REST API
Homo sapiens
MYBL1 is differentially expressed in 326 experiments: 100 organism parts: testis, tonsil, ... (98 more);, 194 disease states: normal, Huntington's disease, ... (192 more);, 111 cell types 404 cell lines 31 compound treatments and 73 other conditions.
Synonyms AMYB, A-myb
Orthologs MYBL1 (Bos taurus)   ENSCING00000002687 (Ciona intestinalis)   MYBL1 (Gallus gallus)   Mybl1 (Mus musculus)   mybl1 (Danio rerio)   Mybl1 (Rattus norvegicus)   BAS1 (Saccharomyces cerevisiae)   Myb (Drosophila melanogaster)   MYBL1 (Xenopus laevis)   MYBL1 (Canis familiaris)   (Compare orthologs)
InterPro Term Myb_DNA-bd, SANT_DNA-bd, MYB-like, C-myb_C, Tscrpt_reg_Wos2-domain
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, nucleus, positive regulation of transcription, DNA-dependent
UniProt Accession Q6LD85, Q495G0, Q495F9, P10243, E7EWZ1
Search EB-eye ENSG00000185697
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-20081, E-GEOD-19639
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
SW480
2
E-GEOD-18005, E-MTAB-37
398 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (51 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-19240, E-GEOD-3998, E-GEOD-3920
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
CD4+ T cell
2
4
E-AFMX-5, E-GEOD-16190, E-TABM-145, E-MEXP-1600, E-MTAB-24, ... (6 experiments)
monocyte
1
3
E-GEOD-11755, E-GEOD-7307, E-GEOD-22373, E-MEXP-583
macrophage
2
E-GEOD-3982, E-GEOD-22373
1
2
E-TABM-130, E-TABM-145
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (62 experiments)

Factor Value U/D Experiments
Huntington's disease
3
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-2514
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
glioblastoma
1
2
E-GEOD-6014, E-GEOD-4290, E-MTAB-37
188 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
5-aza-2'-deoxycytidine + trichostatin A
1
2
E-MEXP-1269, E-GEOD-5230
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
AMP
1
1
E-MEXP-2285
Cxcl12
1
1
E-GEOD-7307
unknown
1
E-GEOD-7307
25 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-19246, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MEXP-2283, E-MEXP-958, E-MEXP-1082, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-1751

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-MEXP-1437, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-21612, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (16 experiments)

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-3494

Processing time: 0.276 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM